The evolving potential of companion diagnostics

Abstract

The scope of companion diagnostics in cancer has undergone significant shifts in the past few years, with increased development of targeted therapies and novel testing platforms. This has provided new opportunities to effect unprecedented paradigm shifts in the application of personalized medicine principles for patients with cancer. These shifts involve assay platforms, analytes, regulations, and therapeutic approaches. As opportunities involving each of these facets of companion diagnostics expand, close collaborations between key stakeholders should be enhanced to ensure optimal performance characteristics and patient outcomes.

Keywords:

• Cancer
• companion diagnostics
• molecular diagnostics
• next-generation sequencing

Disclosure statement

The author reports no conflicts of interest. The author alone is responsible for the content and writing of the paper.